TRIAL DETAIL
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST) |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Unknown |
|||
Phase: |
2 |
Start Date 08/01/2005 |
Age of Trial (yrs) 18.8 |
|
Treatment Phase: |
Neoadjuvant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
Q-CTG-01-V7.0-A1 |
|||
Sponsor: |
Maisonneuve-Rosemont Hospital |
|||
Patient Contact: |
Pierre Dubé, MD |
|||
Contact email: |
pierredube@videotron.qc.ca |
|||
Contact Phone: |
(514) 252-3822 |
|||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
The aim of this study is to demonstrate that the use of Gleevec in initially non-resectable gastrointestinal stromal tumors can lead to allow complete resection in 20% of cases. According to the study description, ". . . The risk of microscopic spreading of the tumor during surgery is very high since intra-abdominal organs are in close relation to each others. To improve survival, it seemed logical to use preoperative Gleevec to reduce tumor size and improve efficacy of the surgical procedure." |
|||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Montreal |
QC |
H1T 2M4 |
Canada |